Clinical trial
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
NCT00365352 · XenoPort, Inc., Industry · Completed
Key facts
| NCT number | NCT00365352 |
|---|---|
| Title | XP13512 vs. Placebo in Patients With Restless Legs Syndrome. |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. |
| Lead sponsor | XenoPort, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | XP13512 600MG, XP13512 1200MG, PLACEBO |
| Enrollment | 325 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Aug 17, 2006 |
| Last update posted | Jul 22, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: